

Curriculum Vitae

Andreas Linkermann



Univ.-Prof. Dr. med. Andreas Linkermann, FASN

Medical Clinic III, Division of Nephrology

Universitätsklinikum Carl Gustav Carus Dresden

Fetscherstr. 74

01307 Dresden, Germany

Phone: +49-(0)351-458-7631

Mobile phone: +49-(0)177-3226147

Assistant phone (Ms Dollfus / Ms Kaul): +49-(0)351-458-3075

Fax: +49-(0)351-458-5333

Email: andreas.linkermann@ukdd.de

Curriculum Vitae

Professional Education

- 1996	Gymnasium - Abitur
08/1996 – 07/1997	Civil service, Neurosurgery Unit, Hospital Minden, Germany
08/1997 – 07/1999	Apprenticeship - Banker (Deutsche Bank AG)
10/1999 – 05/2006	Christian-Albrechts-University, Kiel – Staatsexamen 2006
07/2006 – 09/2016	Department of Internal Medicine and Nephrology, UK-SH, Campus Kiel
07/2008	MD thesis from Institute for Immunology, CAU Kiel (Summa cum laude)
06/2012	„Facharzt für Innere Medizin“
09/2013	„Zusatzbezeichnung Nephrologie“
12/2013 - present	“Oberarzt” (Senior consultant nephrologist)
12/2014	“Habilitation” and “Venia legend” at the CAU
10/2016 – present	Universitätsklinikum Carl Gustav Carus Dresden
10/2016 – present	Deputy director – Division of Nephrology
12/2018 – present	W2 Professorship
12/2018 – present	Heisenberg-Professorship
07/2019 – present	Dresden International Graduate School (DIGS-BB) and Dresden International PhD Programme (DIPP) – Principal investigator
02/2020 – present	International Research Training Group (IRTG 2251)- TransCampus with King’s College London - Principal investigator

Awards

11/2001	Studienstiftung des Deutschen Volkes - Member
06/2009	Faculty award „Fakultätspreis der medizinischen Fakultät der CAU Kiel“
07/2009	Award of the Dean of the Christian-Albrechts University „Dekanatspreis der CAU Kiel“
12/2009	Beigel-Research Award „Beigel’scher Preis“
09/2011	Research award of the German Society for Nephrology (DGfN)
04/2013	ASN Kidney week - faculty member (annually until today)
10/2013	Best Poster award at the German Society of Nephrology (DGfN)
10/2013	EXC306 “Inflammation at Interfaces” - full member
02/2014	Young Innovator Award - American Society of Transplantation (AST)
07/2014	“Carl-Ludwig-Preis” of the German Society of Nephrology (DGfN)
11/2014	STS-Science-Award (Signal Transduction Society)
06/2015	Fellow of the American Society of Nephrology (FASN)
07/2015	“Franz-Volhard-Preis” of the German Society of Nephrology (DGfN)*
10/2015	“GSK Award” at Cold Spring Harbor Asia meeting on Cell Death
03/2016	Honorary Member of the European Academy of Tumor Immunology (EATI)
10/2016	“Rudolf-Pichlmayr-Preis” - German Society of Transplantation (DTG)*
11/2021	Clarivate™ Highly Cited Researcher
05/2022	ERA Award for Research Excellence in Nephrology

*A. Linkermann is the only person who received both the Rudolf-Pichlmayr-Price and the Franz-Volhard-Price

Dresden, in June 2022



Univ.-Prof. Dr. med. Andreas Linkermann, FASN

List of Publications

Andreas Linkermann (14th of June 2022)

Overall impact factors (not counting editorials, case reports and meeting reports): 1.472,62

Average impact factor: 16,01

H-Index: 48 (Web of Science)

In 37 of 92 publications, Linkermann is first, last and/or corresponding author (40,2%).

Primary Publications:

1. Mishima, E., Ito, J., Wu, Z., Nakamura, T., Wahida, A., Doll, S., Tonnus, W., Nepachalovich, P., Eggenhofer, E., Aldrovandi, M., Henkelmann, B., Yamada, K.-I., Wanninger, J., Zilka, O., Sato, E., Feederle, R., Hass, D., Maida, A., Mourao, A.S.D., **Linkermann, A.**, Geissler, E.K., Nakagawa, K., Abe, T., Dedorova, M., Proneth, B., Pratt, D.A. and Conrad, M. (2022) A non-canonical vitamin K cycle is a potent ferroptosis suppressor *Nature* – accepted article in press
2021 IF: 49,962
2. Liao, C.M., Wulfmeyer, V.C., Chen, R., Erlangga, Z., Sinning, J., von Mässenhausen, A., Sörensen-Zender, I., Beer, K., von Vietinghoff, S., Haller, H., **Linkermann, A.**, Melk, A. and Schmitt, R. (2022) Induction of ferroptosis selectively eliminates senescent tubular cells. *American Journal of Transplantation* – online ahead of print
2021 IF: 8,086
3. van Coillie, S., van San, E., Goetschalckx, I., Wiernicki, B., Mukhopadhyay, B., Tonnus, W., Choi, S.M., Roelandt, R., Dumitrascu, C., Lamberts, L., Dams, G., Weyts, W., Huysentruyt, J., Hassannia, B., Ingold, I., Lele, S., Meyer, E., Berg, M., Seurinck, R., Saeys, Y., Vermeulen, A., van Nuijs, A.N.L., Conrad, M., **Linkermann, A.**, Rajapurkar, M., Vandenabeele, P., Hoste, E., Augustyns, K. and Vanden Berghe, T., (2022) Targeting ferroptosis protects against multiorgan dysfunction and death *Nature Communications* – Feb 24;13(1):1046
2021 IF: 14,919
4. Tonnus, W., Locke, S., Meyer, C., Maremonti, F., Eggert, L., von Mässenhausen, A., Bornstein, S.R., Green, D.R. and **Linkermann, A.** (2022) Rubicon-deficiency sensitizes mice to mixed-lineage kinase domain like (MLKL)-mediated kidney ischemia-reperfusion injury. *Cell Death and Disease* – 14;13(3):236
2021 IF: 8,469
5. von Mässenhausen, A., Zamora Gonzalez, N., Maremonti, F., Belavgeni, A., Tonnus, W., Meyer, C., Beer, K., Hannani, M.T., Lau, A., Peitzsch, M., Hoppenz, P., Locke, S., Chavakis, T., Kramann, R., Muruve, D.A., Hugo, C., Bornstein, S.R. and **Linkermann, A.** (2022) Dexamethasone Sensitizes to Ferroptosis by Glucocorticoid Receptor-induced Dipeptidase-1 expression and Glutathione Depletion. *Science Advances* –Feb 4;8(5):eabl8920
2021 IF: 14,136
6. Lau, A., Rahn, J., Chappellaz, M., Chung, H., Benediktsson, H., Bihan, D., von Mässenhausen, A., **Linkermann, A.**, Jenne C.N., Robbins, S.M., Senger, S.L., Lewis, I.A., Chun, J. and Muruve, D.A. (2022) Dipeptidase-1 Governs Renal Inflammation During Ischemia Reperfusion Injury. *Science Advances* – Feb 4;8(5):eabm0142
2021 IF: 14,136
7. Wang, W., Prokopec, J.S., Zhang, Y., Sukhopyasova, M., Shinglot, H., Wang M.T., **Linkermann, A.**, Stewart-Ornstein, J. and Gong, Y.N. (2022) Sensing plasma membrane pore-formation induces chemokine production in survivors of regulated necrosis *Developmental Cell* – Jan 24;57(2):228-245
2021 IF: 12,270

8. Strigli, S., Gopalakrishnan, S., Zeissig, Y., Basic, M., Wang, J., Schwerd, T., Doms, S., Peuker, K., Hartwig, J., Harder, J., Hönscheid, P., Arnold, P., Kurth, T., Kelsen, J.R., Klein, C., Muise, A.M., Mayerle, J., Nambu, R. Török, H.P., Warner, N., **Linkermann, A.**, Muders, M.H., Baretton, G.B., Hampe, J., Aust, D.E., Baines, J.F., Bleich, J., and Zeissig, S. (2021) XIAP regulates Paneth cell homeostasis and the susceptibility to microbial triggers of intestinal inflammation. *Science Immunology* – Nov 5;6(65):cabf7473
2021 IF: 17,727
9. Wu, J., Raman, A., Coffey, N.J., ShengX. Wahba J., Seasock M.J., Ma, Z., Beckerman, P., Laczkó, D., Palmer M.B., Kopp, J.B., Kuo, J.J., Pullen, S.J., Boustany-Kari C.M., **Linkermann, A.** and Susztak, K. (2021) The key role of NLRP3 and STING in APOL1-associated podocytopathy. *The Journal of Clinical Investigation* – Oct 15;131(20):e136329
2021 IF: 14,808
10. Guan, Y., Liang, X., Ma, Z., Hu, H., Liu, H., Miao, Z., **Linkermann, A.**, Hellwege, J.N., Voight, B.F. and Susztak, K. (2021) A single genetic locus controls both expression of DPEP1/CHMP1A and kidney disease development via ferroptosis. *Nature Communications* Aug 23;12(1):5078.
2021 IF: 14,919
11. Tonnus, W.*, Meyer, C.*, Steinebach, C., Belavgeni, A., von Mässenhausen, A., Zamora Gonzalez, N., Maremonti, F., Gemhardt, D., Himmerkus, N., Latk, M., Locke, S., Marschner, J., Li, W., Short, S., Doll, S., Ingold, I., Proneth, B., Daniel, C., Kabgani, N., Kramann, R., Motika, S., Hergenrother, P., Bornstein, S.R., Hugo, C., Becker, J.U., Amann, K., Anders, H.J., Kreisel, D., Pratt, D., Gütschow, M., Conrad, M. and **Linkermann, A.** (2021) Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury *Nature Communications* – Jul 20;12(1):4402 *shared first authors
2021 IF: 14,919
12. Steenblock, C., Richter, S., Berger, I., Barovic, M., Schmid, J., Schubert, U., Jarzebska, N., von Mässenhausen A., **Linkermann A.**, Schürmann, A., Pablik, J., Dienemann, T., Evert, K., Rodionov, R.N., Semenova N.Y., Zinserling, V.A., Gaientdinov, R.R., Baretton, G., Lindemann, D., Solimena, M., Ludwig, B. and Bornstein, S. (2021) Viral infiltration of pancreatic islets in patients with COVID-19 *Nature Communications* – Aug; 17(8):497-510.
2021 IF: 14,919
13. Zeitler, L., Fiore, A., Meyer, C. Russier, M., Suppmann, S., Zanella, G., Gagaro M., Sidhu, S., Seshagiri, S., Ohnmacht, C., Fallarino, F., **Linkermann, A.** and Murray, P.J. (2021) Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism. *eLife* – Mar 1;10:e64806. doi: 10.7554/eLife.64806
2021 IF: 8,140
14. Yang, Y., Tetti, M., Vohra, T., Adolf, C., Seissler, J., Hristov, M., Belavgeni, A., Bidlingmaier, M., **Linkermann, A.**, Mulatero, P., Beuschlein, F., Reincke, M. and Williams, T.M. (2021) BEX1 is differentially expressed in aldosterone-producing adenomas and protects human adrenocortical cells from ferroptosis *Hypertension* – May 5;77(5): 1647-1658
2021 IF: 10,190
15. Demarco, B., Grayczyk, J.P., Bjanas, E., Le Roy, D., Tonnus, W., Assenmacher, C.-A., Radaelli, E., Fettlelet, T., Mack, V., **Linkermann, A.**, Roger, T., Brodsky, I.E., Chen, K.W. and Broz, P. (2020) Caspase-8-dependent gasdermin D cleavage promotes anti-microbial defense but confers susceptibility to TNF-induced lethality *Science Advances* - Nov 18;6(47)
2021 IF: 14,138
16. Plözl, A., Lassnig, C., Tangermann, S., Hromadová, D., Reichart, U., Gawish, R., Müller, K., Moriggl, R., **Linkermann, A.**, Glösmann, M., Kenner, L., Müller, M. and Strobl, B. (2021) TYK2 licenses non-canonical inflammasome activation during endotoxemia *Cell Death and Differentiation* – Feb; 28(2): 748-763
2021 IF: 15,828
17. Južnić L., Peuker K., Strigli A., Brosch M., Herrmann A., Häsler R., Koch M., Matthiesen L., Zeissig Y., Löscher B.S., Nuber A., Schotta G., Neumeister V., Chavakis T., Kurth T., Lesche M., Dahl A., von Mässenhausen A., **Linkermann A.**, Schreiber S., Aden K., Rosenstiel P.C., Franke

- A., Hampe J. and Zeissig S. (2020) SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation *Gut* - Jun 5;gutjnl-2020-321339.
2021 IF: 23,059
18. Fang X., Cai Z., Wang H., Han D., Cheng Q., Zhang P., Gao F., Yu Y., Song Z., Wu Q., An P., Huang S., Pan J., Chen H.Z., Chen J., **Linkermann A.**, Min J. and Wang F. (2020) Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis *Circulation research* - Jul 31;127(4):486-501.
2021 IF: 17,367
 19. Belavgeni, A. *, Bornstein, S.R. *, von Mässenhausen, A., Tonnus, W., Stumpf, J., Meyer, C., Othmar, E., Latk, M., Kanczkowski, W., Kroiss, M., Hantel, C., Hugo, C., Fassnacht, M., Ziegler, C.G., Schally, A.V., Krone, N.P. and **Linkermann, A.** (2019) Exquisite Sensitivity of Adrenocortical Carcinomas to Induction of Ferroptosis *Proceedings of the National Academy of Science (PNAS)* Oct 29;116(44):22269-22274 - *shared first authors
2021 IF: 11,205
 20. Mulay, S.R., Honarpisheh, M.M., Foresto-Neto, O., Shi, C., Desai, J., Zhao, Z.B., Marschner, J.A., Popper, B., Buhl, E.M., Boor, P., **Linkermann, A.**, Liapis, H., Bilyy, R., Herrmann, M., Romagnani, P., Belevich, I., Jokitalo, E., Becker, J.U., Anders, H.J. (2019) Mitochondria permeability transition versus necroptosis in oxalate-induced acute kidney injury *Journal of the American Society of Nephrology (JASN)* Oct;30(10):1857-1869.
2021 IF: 10,121
 21. Li, W., Feng, G., Gauthier, J.M., Lokshina, I., Higashikubo, R., Evans, S., Liu, X., Hassan, A., Tanaka, S., Cicka, M., Hsiao, H.-M., Ruiz-Perez, D., Bredemeyer, A., Gross R.W., Mann, D.L., Tyurina Y.Y., Gelman, A.E., Kagan, V.E., **Linkermann, A.**, Lavine, K.J., and Kreisel, D. (2019) Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation *The Journal of Clinical Investigation (JCI)* – Feb 26;130.
2021 IF: 14,808
 22. Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wie, J., Gu, S., Gao, F., Zhu, N., Yin, X., Cheng, Q., Zhang, P., Dai, W., Chen, J., Yang, F., Yang, H.-T., **Linkermann, A.***, Gu, W.* , Min J. and Wang, F.* (2019) Ferroptosis as a novel target for protection against cardiomyopathy *Proceedings of the National Academy of Science (PNAS)* – Feb 12;116(7):2672-2680. *shared corresponding authors
2021 IF: 11,205
 23. Aljabri, A., Vijayan, V., Stankov, M., Nikolin, C., Figueiredo, C., Blasczyk, R., Becker, J.U., **Linkermann, A.**, Immenschuh, S. (2019) HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway *Cell Death and Disease* - Mar 8;10(3):235
2021 IF: 8,469
 24. Lafont, E., Draber P., Rieser E., Reichert M., Kupka S., de Miguel D., Draberova H., von Mässenhausen A., Bhamra A., Henderson S., Wojdyla K., Chalk A., Surinova S., **Linkermann A.** and Walczak, H. (2018) M1-ubiquitin- and NEMO-recruited TBK1/IKKε prevent TNF-induced cell death by RIPK1 phosphorylation *Nature Cell Biology (NCB)* – Dec;20(12):1389-1399
2021 IF: 28,824
 25. Stoppe, C., Averdunk, L., Goetzenich, A., Soppert, J., Marlier, A., Kraemer, S., Vieten, J., Coburn, M., Kowark, A., Kim, B-S., Marx, G., Rex, S., Ochi, A., Leng, L., Moeckel, G., **Linkermann, A.**, El Bounkari, E., Zarbock, A., Bernhagen, J., Djudjaj, S., Bucala, R. and Boor, P. (2018) The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery *Science translational medicine (STM)* - 16 May 18; 10, ean4886
2021 IF: 17,956
 26. Bruni, A., Pepper, A.R., Pawlick, R.L., Gala-Lopez, B., Gamble A.F., Kin, T., Seeberger, K., Korbitt, G.S., Bornstein, S.R., **Linkermann, A.***, Shapiro A.M*. (2018) Ferroptosis-inducing agents compromise in vitro human islet viability and function *Cell death and disease (CDDis)* – 2018-9:595 *shared senior authors
2021 IF: 8,469

27. Martin-Sanchez, D., Fontecha-Barriuso, M., Carrasco, S., Sanchez-Niño, M., von Mässenhausen, A., **Linkermann, A.**, Cannata-Ortiz, P., Ruiz-Ortega, M., Egido, J., Ortiz, A. and Sanz, A.B. (2018) TWEAK and RIPK1 mediate a second wave of cell death during AKI. *Proceedings of the National Academy of Science (PNAS)* – Apr 17;115(16):4182-4187
2021 IF: 11,205
28. Gaschler M.M., Hu F., Feng H., **Linkermann A.**, Min W. and Stockwell B.R. (2018) Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis. *ACS Chem Biol.* – Apr 20;13(4):1013-1020
2021 IF: 5,100
29. von Mässenhausen, A.* , Tonnus, W.* , Himmerkus, N., Parmentier, S., Saleh, D., Rodriguez, D., Ousingsawat, J., Ang R.L., Weinberg, J.M., Sanz, A.B., Ortiz, A., Zierleyn, A., Becker, J.U., Baratte, J., Desban, N., Bach, S., Schiessl, I.M., Nogusa, S., Balachandran, S., Anders, H.J., Ting, A.T., Bleich, M., Degtrev, A., Kunzelmann, K., Bornstein, S.R., Green, D.R., Hugo, C., and **Linkermann, A.** (2018) Phenytoin inhibits necroptosis *Cell Death and Disease* Mar 2;9(3):359.
2021 IF: 8,469
30. Schreiber A., Rousselle A., Becker J.U., von Mässenhausen A., **Linkermann A.** and Kettritz R. (2017) Necroptosis controls NETs generation and mediates complement activation, endothelial damage and autoimmune vasculitis *Proceedings of the National Academy of Science (PNAS)* Nov 7;114(45):E9618-E9625
2021 IF: 11,205
31. Martens S., Takahashi N., Goossens V., Hofmans S., Van der Veken P., Joossens J., Augustyns K., Jeong M., Lee E.W., Song J, Tonnus W., Feldmann F., Fulda S., Bräsen J.H., **Linkermann A.** and Vandenabeele P. (2017) Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury *Cell death and disease* – Jun 29;8(6):e2904
2021 IF: 8,469
32. Gong Y.-N., Guy C., Olason H., Becker J.U., Yang M., Fitzgerald P., **Linkermann A.*** and Green D.R.* (2017): ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. *Cell* Apr 6;169(2):286-300, *Corresponding authors
2021 IF: 41,582
33. Greve A.S. *, Skals M. *, Fagerberg S.K., Tonnus W., Ellermann-Eriksen S., Evans R.J., **Linkermann A.*** and Praetorius H.E.* (2017) P2X1, P2X4 and P2X7 receptor knock out mice expose differential outcome of sepsis induced by β -haemolysin producing Escherichia coli. *Frontiers in Cellular and Infection Biology* 2017 Apr 6;7:113. *Corresponding authors
2021 IF: 6,684
34. Geismann C, Grohmann F, Dreher A, Häsler R, Rosenstiel P, Legler K, Hauser C, Egberts JH, Sipos B, Schreiber S, **Linkermann A**, Hassan Z, Schneider G, Schäfer H, Arlt A. (2017) Role of CCL20 mediated immune cell recruitment in NF- κ B mediated TRAIL resistance of pancreatic cancer. *Biochim Biophys Acta – Molecular Cell Research.* 2017 May;1864(5):782-796.
2021 IF: 4,739
35. Ousingsawat J, Cabrita I, Wanitchakool P, Sirianant L, Krautwald S, **Linkermann A**, Schreiber R, Kunzelmann K (2017) Ca²⁺ signals, cell membrane disintegration, and activation of TMEM16F during necroptosis. *Cellular and Molecular Life Sciences (CMLS)* Jan;74(1):173-181
2021 IF: 9,261
36. Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco J, Cannata-Ortiz P, Sanchez-Nino MD, Ortega MR, Egido M, **Linkermann A**, Ortiz A and Sanz AB (2017) Ferroptosis, but not necroptosis, plays an important role in nephrotoxic folic acid-induced acute kidney injury *Journal of the American Society of Nephrology (JASN)* Jan;28(1):218-229.
2021 IF: 10,121
37. Günther C., He G., Kremer A., Murphy J., Petrie E., Amann K., Vandenabeele P., **Linkermann A.**, Poremba C., Schleicher U., Dewitz C., Krautwald S., Neurath M.F., Becker C. and Wirtz S. (2016) MLKL mediates programmed hepatocellular necrosis independent of RIPK3 during hepatitis. *The Journal of Clinical Investigation (JCI)* Nov 1;126(11):4346-4360

- 2021 IF: 14,808**
38. Gautheron J., Vucur M., Schneider A.T., Severi I., Roderburg C., Roy S., Bartneck M., Schrammen P., Berriel Diaz M., Ehling J., Gremse F., Heymann F., Koppe C., Lammers T., Kiessling F., Van Best N., Pabst O., Courtois G., **Linkermann A.**, Krautwald S., Neumann U., Tacke F., Trautwein C., Green D.R., Longerich T., Frey N., Lüdde M., Blüher M., Herzig S., Heikenwalder M. and Lüdde, T (2016) The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance *Nature Communications* 21;7:11869
2021 IF: 14,919
39. Martinez J., Cunha L., Park S., Yang M., Lu Q., Orchard R., Li Q.-Z., Yan M., Janke M., Guy C., **Linkermann A.**, Virgin H. and Green D.R. (2016) LC3-associated phagocytosis links clearance of dying cells to auto-inflammation and lupus-like disease in mice *Nature* May 5;533(7601):115-9.
2021 IF: 49,962
40. Corcelle-Termeau, E., Vindeløv S.D., Hämälistö S., Mograbi B., Keldsbo A., Bräsen J.H., Favaro E., Adam D., Szyniarowski P., Hofman P., Krautwald S., Farkas T., Petersen N.H.T., Rohde M., **Linkermann A.**, Jäättelä M. (2016) Excess sphingomyelin disturbs ATG9A trafficking and autophagosome closure *Autophagy* May 3;12(5):833-49
2021 IF: 16,016
41. Mulay S.R., Jyaysi D., Kumar V.R. Eberhard J.N., Thomasova D., Romoli S., Grigorescu M., Kulkarni O.P., Popper B., Vielhauer V., Zuchtriegel G., Reichel C., Bräsen J.H., Romagnani P., Bilyy R., Munoz L.E., Herrmann M., Liapis H., Krautwald S., **Linkermann A.** and Anders H.J. (2016) Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis in kidney stone disease *Nature Communications* Jan 28;7:10274
2021 IF: 14,919
42. Desai J, Vr S.K., Mulay S.R., Konrad L., Romoli S., Schauer C., Herrmann M., Bilyy R., Müller S., Popper B., Nakazawa D., Weidenbusch M., Thomasova D., Krautwald S., **Linkermann A.**, Anders H.J. (2015) Neutrophil extracellular trap formation can involve RIPK1-RIPK3-MLKL signalling *Eur J Immunol.* (2016) Jan;46(1):223-9
2021 IF: 5,532
43. Fauster A., Rebsamen M., Huber K., Bigenzahn J., Stukalov A., Lardeau C.-H., Scorzoni S., Bruckner M., Gridling M., Parapatics M., Colinge J., Bennett K., Kubicek S., Krautwald S., **Linkermann A.** and Superti-Furga G. (2015) A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. *Cell Death and Disease*, May 21;6:e1767.
2021 IF: 8,469
44. Ising C., Koehler S., Brähler S., Merkwirth C., Höhne M., Baris O.R., Hagmann H., Kann M., Fabretti F., Dafinger C., Bloch W., Schermer B., **Linkermann A.**, Brüning J.C., Kurschat C.E., Müller R.U., Wiesner R.J., Langer T., Benzing T., Brinkkoetter P.T. (2015) Inhibition of insulin/IGF-1 receptor signaling protects from mitochondria-mediated kidney failure. *EMBO Molecular Medicine*, Feb 2;7(3):275-87.
2021 IF: 12,137
45. **Linkermann A.**, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, Weinlich R, Vanden Berghe T, Vandenabeele P, Pasparakis M, Bleich M, Weinberg JM, Reichel CA, Bräsen JH, Kunzendorf U, Anders HJ, Stockwell BR, Green DR, Krautwald S. (2014) Synchronized renal tubular cell death involves ferroptosis. *Proceedings of the National Academy of Science (PNAS)* 25;111(47):16836-41
2021 IF: 11,205
46. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M, Gautheron J, Roderburg C, Borg N, Reisinger F, Hippe HJ, **Linkermann A.**, Wolf MJ, Rose-John S, Lüllmann-Rauch R, Adam D, Flögel U, Heikenwalder M, Luedde T, Frey N. (2014) RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. *Cardiovascular Research* Jul 15;103(2):206-16
2021 IF: 10,787
47. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., **Linkermann, A.** and Stockwell, B.R. (2014) Ferrostatins selectively inhibit lipid

- peroxidation in diverse disease models involving ferroptotic cell death. *Journal of the American Chemical Society (JACS)*, 26;136(12):4551-6.
2021 IF: 15,419
48. Sosna, J., Voigt, S., Mathieu, S., Lange, A., Thon, L., Davarnia, P., Herdegen, T., **Linkermann, A.**, Rittger, A., Chan, F.K.M., Kabelitz, D., Schütze, S., Adam, D. (2014) TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct and independent routes to programmed necrotic cell death. *Cellular and Molecular Life Sciences (CMLS)*, 71(2):331-48.
2021 IF: 9,261
49. Tait S.W.G., Oberst A., Quarato, G., Milasta, S., Haller, M., Wang, R., Yatim, N., Albert, M., Krautwald, S., **Linkermann, A.** and Green D.R. (2013): Widespread depletion of mitochondria does not compromise RIPK3-mediated necroptosis. *Cell Reports* 27;5(4):878-85.
2021 IF: 9,423
50. Lau, A., Wang, S., Jiang, J., Haig, A., Pavlosky, A., **Linkermann, A.**, Zhang, Z.-X., Jevnikar, A.M. (2013). RIPK3 mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. *American Journal of Transplantation* 13(11):2805-18.
2021 IF: 8,086
51. **Linkermann, A.**, Bräsen J.H., Darding, M., Jin, M.K., Sanz, A.B., Heller, J.-O., De Zen, F., Weinlich, R., Ortiz, A., Walczak, H., Weinberg, J.M., Green, D.R., Kunzendorf, U., Krautwald, S. (2013). Two Independent Pathways of Regulated Necrosis Mediate Ischemia-Reperfusion Injury, *Proceedings of the National Academy of Science (PNAS)* 16;110(29):12024-9.
2021 IF: 11,205
52. **Linkermann, A.**, Heller, J.-O., Prokai, A., Weinberg, J.M., De Zen, F., Himmerkus, N., Szabo, A.J., Bräsen, J.H., Kunzendorf, U., Krautwald, S. (2013). Osmotic Nephrosis and Contrast-Induced Acute Kidney Injury are prevented by the RIP1-kinase Inhibitor Necrostatin-1 in Mice. *Journal of the American Society of Nephrology (JASN)* Nov 24(10):1545-57.
2021 IF: 10,121
53. **Linkermann, A.**, Bräsen, J.H., De Zen, F., Weinlich, R., Schwendener, R.A., Green, D.R., Kunzendorf, U., Krautwald, S. (2012). Dichotomy between RIP1- and RIP3-mediated Necroptosis in Tumor Necrosis Factor α -induced Shock. *Molecular Medicine* May 9;18:577-86.
2021 IF: 6,354
54. **Linkermann, A.**, Bräsen, J.H., Himmerkus, N., Liu, S., Huber, T.B., Kunzendorf, U., Krautwald, S. (2011). RIP1-mediated necroptosis essentially contributes to renal ischemia/reperfusion injury. *Kidney International* 81, 751-761.
2021 IF: 10,612
55. **Linkermann, A.**, Himmerkus, N., Rölver, L., Bleich, M., Bräsen, J.H., Kunzendorf, U., Krautwald, S. (2011). Blocking FasL in acute lethal Cisplatin induced renal failure prolongs survival in mice via two different mechanisms. *Kidney International* 79, 169-178.
2021 IF: 10,612
56. Krautwald, S., Ziegler, E., Rölver, L., **Linkermann, A.**, Kayser, K., Mortimer-Klingebiel, S., Kunzendorf, U. (2010): Effective blockage of both the extrinsic and intrinsic pathways of apoptosis in mice by TAT-crmA. *Journal of Biological Chemistry*, Jun 25;285(26):19997-20005.
2021 IF: 5,157
57. Lettau M., Pieper J., Gerneth A., Lengl-Janßen B., Voss M., **Linkermann A.**, Schmidt H., Gelhaus C., Leippe M., Kabelitz D., Janssen O. (2010): The adapter protein Nck: Role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. *Protein Science*, Apr;19(4):658-69.
2021 IF: 6,725
58. **Linkermann, A.**, Gelhaus, C., Lettau, M., Qian, J., Kabelitz, D., Janssen, O. (2009): Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes, *BBA-Proteins and Proteomics*, 1794; 168-176.
2021 IF: 3,036
59. Lettau, M., Qian, J., **Linkermann, A.**, Larose, L., Kabelitz, D., Janssen O (2006). The adaptor protein Nck interacts with Fas Ligand: Guiding the death factor to activation clusters and the

immunological synapse. *Proceedings of the National Academy of Science (PNAS)* 15 (103), 5911-5916.

2021 IF: 11,205

Cumulative Impact factor 2021 of primary publications:	791,854
Average impact factor 2021 of primary publications:	13,42

Reviews and Guidelines:

1. Maremonti, F., Meyer, C. and **Linkermann, A.** (2022) - Mechanisms and Models of Kidney Tubular Necrosis and Nephron Loss. *Journal of the American Society of Nephrology (JASN)* accepted review – online ahead of print
2021 IF: 10,121
2. Steenblock C., Schwarz P.E.H., Ludwig B., **Linkermann A.**, Zimmet P., Kulebyakin K., Tkachuk V.A., Markov A.G., Lehnert H., de Angelis M.H., Rietzsch H., Rodionov R.N., Khunti K., Hopkins D., Birkenfeld A.L., Boehm B., Holt R.I.G., Skyler J.S., DeVries J.H., Renard E., Eckel R.H., Alberti K., Geloneze B., Chan J.C., Mbanya J.C., Onyegbutulem H.C., Ramachandran A., Basit A., Hassanein M., Bewick G., Spinaz G.A., Beuschlein F., Landgraf R., Rubino F., Mingrone G. and Bornstein S.R. (2021) COVID-19 and metabolic disease: mechanisms and clinical management. *Lancet Diabetes Endocrinol.* 2021 Nov;9(11):786-798.
2021 IF: 32,069
3. Tonnus, W., Belavgeni, A., Beuschlein, F., Eisenhofer, G., Fassnacht, M., Kroiss, M., Krone, N., Reincke, M., Bornstein, S. and **Linkermann, A.** (2021) The Role of Regulated Necrosis in Endocrine Diseases *Nature Reviews Endocrinology – Aug; 17(8):497-510*
2021 IF: 43,330
4. Belavgeni A., Meyer C., Stumpf J., Hugo C. and **Linkermann A.** (2020) Ferroptosis and Necroptosis in the Kidney. *Cell Chemical Biology* - Apr 16;27(4):448-462
2021 IF: 8,116
5. Steglich, A., Hickmann, L., **Linkermann, A.**, Bornstein, S., Hugo, C., Todorov, V.T. (2020) Beyond the Paradigm: Novel Functions of Renin-Producing Cells. *Rev Physiol Biochem Pharmacol.* 2020 177:53-81
2021 IF: 5,545
6. Del Re, D., Amgalan, D., **Linkermann, A.**, Liu, Q and Kitsis, R.N. (2019) Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. *Physiological Reviews* Oct 1;99(4):1765-1817
2021 IF: 37,312
7. Tonnus W., Gembardt F., Latk M., Parmentier S., Hugo S., Bornstein S.R. and **Linkermann A.** (2019) The Clinical Relevance of Necroinflammation – Highlighting the Importance of Acute Kidney Injury and the Adrenal Glands. *Cell Death and Differentiation* Jan;26(1):68-82
2021 IF: 15,828
8. Bornstein S.R., Steenblock C., Chrousos G.P., Schally A.V., Beuschlein F., Kline G., Krone N.P., Licinio J., Wong M.L., Ullmann E., Ruiz-Babot G., Boehm B.O., Behrens A., Brennand A., Santambrogio A., Berger I., Werdermann M., Sancho R., **Linkermann A.**, Lenders J.W., Eisenhofer G. and Andoniadou C.L. (2018) Stress-inducible Stem Cells: A new View on Endocrine, Metabolic and Mental Disease? *Molecular Psychiatry* Sep 21. doi: 10.1038/s41380-018-0244-9.
2021 IF: 15,992
9. Sarhan, M., Land, W., Tonnus, W., Hugo, C. and **Linkermann, A.** (2018) Origin and Consequences of Necroinflammation. *Physiological Reviews* Apr 1;98(2):727-780.
2021 IF: 37,312
10. Sarhan, M., von Mässenhausen, A., Hugo, C. and **Linkermann, A.** (2018) Immunological consequences of kidney cell death *Cell Death and Disease* – Jan 25;9(2):114.
2021 IF: 8,469
11. Martin-Sanchez, D., Fontecha-Barriuso, M., Sanchez-Niño, M.D., Ramos, A.M., Cabello, R., Gonzalez-Enguita, C., **Linkermann, A.**, Sanz, A.B., Ortiz, A. (2018) Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields *Cell Death and Disease* – Jan 25;9(2):118

- 2021 IF: 8,469**
12. Galluzzi L., [...], **Linkermann A.** [...] and Kroemer G. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation* – Mar;25(3):486-541
2021 IF: 15,828
 13. Stockwell, B.R., {...} **Linkermann A.**, {...} (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell* – Oct 5;171(2):273-285
2021 IF: 41,582
 14. Tonnus, W. and **Linkermann, A.** (2017) The *in vivo* relevance for regulated necrosis *Immunological Reviews* May;277(1):128-149
2021 IF: 12,988
 15. Land W.G., Agostinis P., Gasser, S., Garg, A.G. and **Linkermann, A.** (2016) DAMP – Induced Allograft and Tumor Rejection: The Circle is Closing. *American journal of Transplantation* – Dec;16(12):3322-3337
2021 IF: 8,086
 16. Land W.G., Agostinis P., Gasser, S., Garg, A.G. and **Linkermann, A.** (2016) Transplantation and Damage Associated Molecular Patterns (DAMPs). *American journal of Transplantation* – Dec; 16(12):3338-3361
2021 IF: 8,086
 17. **Linkermann A.** (2016). Non-apoptotic cell death in acute kidney injury and transplantation. *Kidney International* 89, 46–57
2021 IF: 10,612
 18. Degtarev A. and **Linkermann A.** (2016). Generation of small molecules to interfere with regulated necrosis. *Cellular and Molecular Life Sciences*. 73(11-12):2251-67.
2021 IF: 9,261
 19. Kers J., Leemans J.C. and **Linkermann A.** (2016) An overview on pathways of regulated necrosis in kidney cell death. *Seminars in Nephrology* 73(11-12):2123-4.
2021 IF: 5,299
 20. Klionsky, D.J. [...], **Linkermann A.**, [...](2016) Guidelines for the use and interpretation of assays for monitoring autophagy (2nd edition) *Autophagy* 2016 Jan 2;12(1):1-222.
2021 IF: 16,016
 21. Simeoni L., Thurm C. Kritikos A. and **Linkermann A.** (2016) Redox homeostasis, T cells and kidney disease: three faces in the dark. *Clinical Kidney Journal* Feb;9(1):1-10.
2021 IF: 4,452
 22. Zhao H, Jaffer T, Eguchi S, Wang Z, **Linkermann A**, Ma D. (2015) Role of necroptosis in the pathogenesis of solid organ injury. *Cell Death Dis*. Nov 19;6:e1975
2021 IF: 8,469
 23. Mulay, S.R., **Linkermann A.** and Anders H.J. (2015): Necroinflammation in kidney disease. *Journal of the American Society of Nephrology (JASN)* Jan;27(1):27-39
2021 IF: 10,121
 24. **Linkermann, A.**, Stockwell, B.R., Krautwald, S. and Anders, A. (2014). Regulated Cell Death and Inflammation – An Auto-amplification Loop causes Organ Failure. *Nature Reviews Immunology* 14(11):759-67
2021 IF: 53,106
 25. Galluzzi L., [...], **Linkermann A.** [...] and Kroemer G.: Recommendations of the nomenclature committee on cell death. *Cell Death and Differentiation* Jan;22(1):58-73.
2021 IF: 15,828
 26. **Linkermann, A.**, Chen G., Dong, G., Kunzendorf, U., Krautwald, S., Dong Z. (2014). Regulated Cell Death in Acute Kidney Injury. *Journal of the American Society of Nephrology (JASN)* 25(12):2689-701
2021 IF: 10,121

27. **Linkermann, A.** and Green, D.R. (2014) Mechanisms of Disease: Necroptosis. *New England Journal of Medicine (NEJM)* (350, (5): 455-465)
2021 IF: 91,245
28. Vanden Berghe, T.*, **Linkermann, A.***, Takahashi, N., Walczak, H., Vandenabeele P. (2014). Regulated Necrosis: An Expanding Wealth of Cell Death Pathways. *Nature Reviews - Molecular Cell Biology* (23, 15(2): 135-47) *shared first authorship
2021 IF: 94,444
29. **Linkermann, A.**, Hackl, M., Kunzendorf, U., Walczak H., Krautwald, S. and Jevnikar A.M. (2013) Necroptosis in Immunity and Ischemia-Reperfusion Injury. *American Journal of Transplantation* (13(11):2797-804) – cover story
2021 IF: 8,086
30. **Linkermann, A.** De Zen, F., Weinberg, J., Kunzendorf, U., Krautwald, S. (2012). Programmed Necrosis in Acute Kidney Injury. *Nephrology Dialysis Transplantation* (invited review) Sep;27(9):3412-9.
2021 IF: 5,992
31. **Linkermann, A.**, Qian, J., Lettau, M., Kabelitz, D., Janssen O. (2005): Considering Fas Ligand as a target for therapy. *Expert Opinion on Therapeutic Targets* 9(1), 119-34
2021 IF: 6,902
32. **Linkermann, A.**, Qian, J., Janssen, O. (2003): Slowly getting a clue on CD95 ligand biology. *Biochemical Pharmacology*, 66, 1417-1426
2021 IF: 5,858
33. Janssen, O., Qian, J., **Linkermann, A.**, Kabelitz, D. (2003): CD95L – death factor and costimulatory molecule? *Cell Death and Differentiation*, 10, 1215-1225
2021 IF: 15,828

Cumulative Impact factor 2021 of reviews and guidelines:	680,773
Average impact factor 2021 of reviews and guidelines:	20,629

Editorials:

1. Belavgeni, A., Maremonti, F., Stadtmüller, M., Bornstein, S.R. and **Linkermann, A.** (2022) Schwann cell necroptosis in diabetic neuropathy *PNAS* 26;119(17)e2204049119
2. Schnieke A., Locke S. and **Linkermann A.** (2020) Precondition your donor pig for your successful allograft *American Journal of Transplantation* – Dec;20(12):3275-3276
3. Belavgeni A., Bornstein S.R. and **Linkermann A.** (2019) Prominin-2 Suppresses Ferroptosis Sensitivity *Developmental Cell* Dec 2;51(5):548-549
4. **Linkermann A** and Kulms D (2019) Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization *Cell Death and Disease* Dec 4;10(12):910
5. Tonnus W and **Linkermann A.** (2019) Gasdermin D and Pyroptosis in AKI *Kidney International* Nov;96(5):1061-1063
6. Tonnus W, Belavgeni A, Xu Y, **Linkermann A.** (2019) Don't trick me twice *Kidney International* Apr;95(4):736-738
7. **Linkermann A.** (2019) Death and Fire *Cell Death and Differentiation* Jan;26(1):1-3
8. **Linkermann A.**, Parmentier, S., and Hugo C. (2018) We Aim2 inflame *JASN*, Apr;29(4):1077-1079
9. **Linkermann A.**, Stockwell B.R. and Vanden Berghe, T. (2017) Heavy Metal Suicide *AJP renal* – Oct 1;313(4):F959-F960
10. Tonnus W., Gembarde F., Hugo C. and **Linkermann A.** (2017) Die later with ESCRT! *Oncotarget* – Jun 27;8(26):41790-41791
11. Todorov, V. and **Linkermann A.** (2017) Back to the Roots of Regulated Necrosis *Journal of Cell Science (JCS)* Feb;216(2):303-304

12. Tonnus, W., Hugo C. and **Linkermann A.** (2017) Gimme a Complex! Resident mononuclear phagocytes in the kidney as monitors of circulating antigens and immune complexes. *Kidney International* Feb;91(2):267-269
13. Schulte, K. and **Linkermann A.** (2016) Welcome to the Jungle – The Kidney during Sepsis. *American Journal of Respiratory and Critical Care Medicine (AJRCCM)* Sep 15;194(6):649-50
14. Tonnus, W. and **Linkermann A.** (2016) “Death is my Heir” – Ferroptosis Connects Cancer Pharmacogenomics and Ischemia-Reperfusion Injury. *Cell Chemical Biology* Vol. 23, Issue 2, p225–235.
15. **Linkermann A.**, Konstantinidis K, Kitsis RN. (2015) Catch me if you can: targeting the mitochondrial permeability transition pore in myocardial infarction. *Cell Death Differ.* 2016 Jan;23(1):1-2
16. Vanden Berghe, T. and **Linkermann, A.** (2014). Take my breath away: Necrosis in kidney transplants kills the lungs! *Kidney International* Apr;87(4):680-2.
17. **Linkermann A.**, Kunzendorf, U. and Krautwald S (2014). Phosphorylated MLKL causes plasma membrane rupture. *Molecular and Cellular Oncology* Aug 13;1(1):e29915
18. Krautwald S. and **Linkermann A.** (2014). The fire within – pyroptosis in the kidney. *AJP renal*, 306(2):F168-9

Clinical Case Reports:

1. Foltys D., **Linkermann A.**, Heumann A., Hoppe-Lotichius M., Heise M., Schad A., Schneider J., Bender K., Schmid M., Mauer D., Peixoto N., Otto G. Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report. *Transplant Proc.* 2009 Jul-Aug;41(6):2639-42.

Meeting Reports:

1. Bornstein SR, Guan K, Brunßen C, Mueller G, Kamvissi-Lorenz V, Lechler R, Trembath R, Mayr M, Poston L, Sancho R; IRTG Study Group.; Ahmed S, Alfar E, Aljani B, Alves TC, Amiel S, Andoniadou CL, Bandral M, Belavgeni A, Berger I, Birkenfeld A, Bonifacio E, Chavakis T, Chawla P, Choudhary P, Cujba AM, Delgadillo Silva LF, Demcollari T, Drotar DM, Duin S, El-Agroudy NN, El-Armouche A, Eugster A, Gado M, Gavalas A, Gelinsky M, Guirgus M, Hansen S, Hanton E, Hasse M, Henneicke H, Heller C, Hempel H, Hogstrand C, Hopkins D, Jarc L, Jones PM, Kamel M, Kämmerer S, King AJF, Kurzbach A, Lambert C, Latunde-Dada Y, Lieberam I, Liers J, Li JW, **Linkermann A.**, Locke S, Ludwig B, Manea T, Maremonti F, Marinicova Z, McGowan BM, Mickunas M, Mingrone G, Mohanraj K, Morawietz H, Ninov N, Peakman M, Persaud SJ, Pietzsch J, Cachorro E, Pullen TJ, Pyrina I, Rubino F, Santambrogio A, Schepp F, Schlinkert P, Scriba LD, Siow R, Solimena M, Spagnoli FM, Speier S, Stavridou A, Steenblock C, Strano A, Taylor P, Tiepner A, Tonnus W, Tree T, Watt F, Werdermann M, Wilson M, Yusuf N, Ziegler CG. (2021) The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. *Horm Metab Res.* 2021 Mar;53(3):204-206. doi: 10.1055/a-1377-6583.
2. **Linkermann A.** and Kulms D. (2019) Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization. *Cell Death and Disease* 2019 Dec 4;10(12):910.

Books:

1. Tonnus W., Belavgeni A. and **Linkermann A.** Regulated Necrosis and Its Immunogenicity (2021). *Clinical Immunology* – 6th Edition - *in press*
2. Galluzzi L., **Linkermann A.**, Kepp O. and Kroemer G. Pathophysiology of Cancer Cell Death (2021). *Abeloff's Clinical Oncology* 6th Edition – *in press*
3. Tonnus W. and **Linkermann A.** Regulated Necrosis and Its Immunogenicity (2018). *Clinical Immunology* – 5th Edition - ISBN: 978-0-7020-6896-6; PII: B978-0-7020-6896-6.00013-2
4. Tonnus W, Al-Mekhlafi M, Hugo C, **Linkermann A.** (2018) Assessment of *In Vivo* Kidney Cell Death: Acute Kidney Injury *Methods Mol Biol.* 1857:135-144. doi: 10.1007/978-1-4939-8754-2_13.

5. Tonnus W, Al-Mekhlafi M, Gembardt F., Hugo C, **Linkermann A.** (2018) Assessment of *In Vivo* Kidney Cell Death: Glomerular Injury *Methods Mol Biol.* 1857:145-151. doi: 10.1007/978-1-4939-8754-2_14.
6. **Linkermann, A.** Necrotic cell death in ischemia reperfusion injury (2014). *Necrotic Cell Death.* Springer/Humana Press (Vol. 2). Zheng Dong and Peter Vandenabeele (Ed.), ISBN 978-1-4614-8220-8
7. Kunzendorf, U., **Linkermann, A.**, Rölver L., Heemann, U. (2010): Tacrolimus: Evidenz und Erfahrung. *Kardiovaskulärer Schutz nach Transplantation*, Band 3, 1-16. Permanyer, 2010, ISBN 8499261612
8. **Linkermann, A.**, Qian, J., Janssen, O., Chapter 7, Retrograde Fas Ligand signalling (2006). *Fas signaling.* Landes Bioscience, Wajant H (Ed.), VIII, Hardcover, ISBN: 978-0-387-32172-1

Clinical Reviews in German Journals:

1. **Linkermann A.** (2015): Bedeutung regulierter Zelltodprogramme für die Transplantation solider Organe. *Der Nephrologe*, 2015/2: 100-106.
2. **Linkermann A.** (2014): Regulated necrosis – A pathophysiological principle of acute kidney injury. *Dialyse aktuell*, 18(8): 430-433
3. Feldkamp, T, **Linkermann, A.** (2013): Immunsuppressive Therapie nach Nierentransplantation - Vermeidung von Steroiden und Calcineurin-Inhibitoren. *Der Nephrologe*, 3:220-225.
4. Kunzendorf, U., **Linkermann, A.** (2011): Renal Transplantation – Specific aspects regarding elder dialysis patients. *Dialyse aktuell*, 15(10): 568-575
5. **Linkermann, A.**, Kunzendorf, U. (2010): Orale Tolvaptan-Therapie: Ist diese sicher und effektiv zur Behandlung der chronischen Hyponatriämie? *Der Nephrologe*, 5:239–241
6. **Linkermann, A.**, Kunzendorf, U. (2007): Tolvaptan ist ein selektiver oraler Vasopressin-V2-Rezeptor-Antagonist für die Therapie der Hyponatriämie. *Der Nephrologe*, 2:121–123

Patents:

1. **06/2016:** Sorafenib tosylate as necroptosis inhibitor (Patent number 11726338001, Patent application number GB1609641.4).
2. **03/2020:** Nec-1f, a dual inhibitor of necroptosis and ferroptosis (Patent number 20160943.5, patent issued).

Editorial activities:

Cell Death and Disease (NPG):	Senior Editor
American Journal of Transplantation (AJT)	Editorial Board Member
Journal of the American Society of Nephrology (JASN)	Editorial Board Member
American Journal of Physiology – Renal Physiology:	Editorial Board Member (2014-2021)
Frontiers in Pharmacology (section on renal pharmacology)	Editorial Board Member
Molecular and Cellular Oncology:	Editorial Board Member
Kidney360 (ASN)	Editorial Board Member
Clinical Kidney Journal (former NDT Plus):	Senior Editor/Basic Science
Cell Death and Differentiation (NPG):	Guest Editor 2018
Cellular and Molecular Life Sciences:	Guest Editor 2016
Seminars in Nephrology:	Guest Editor 2015

Scientific reviewer activities

Scientific reviewer: Verified Publons report attached: Reviewed for more than 60 journals, including The Lancet, Cell, nature and others (99th percentile for verified review contributions on Publons).

International grant application referee: DFG, ERC, MRC, CRUK, FWO, SNF, Korean Research Society etc.

Memberships

- European Academy of Tumor Immunology – honorary member (since 2015)
- American Society of Nephrology (FASN since 2015, member since 2010)
- American Society of Transplantation (honorary member 2013)
- International Society of Nephrology (ISN - since 2013)
- Deutsche Transplantationsgesellschaft (since 2010)
- Deutsche Gesellschaft für Nephrologie (since 2009)
- European Cell Death Organization (ECDO – since 2009)
- Akademie Niere (since 2008)
- Deutsche Gesellschaft für Immunologie (since 2004)
- Signal transduction society (STS), since 2003, Member of the scientific council since 2021
- European Renal Association (ERA), since 2022

Specific scientific achievements

- First description of the *in vivo* relevance of ferroptosis (PNAS 2014 – first author)
- First description of necroptosis in the kidney (Kidney International 2012 – first author)
- First detection of necroptosis in a solid organ transplant (AJT cover story 2013 – first author)
- First detection of ferroptosis in a solid organ transplant (JCI 2019 – co-author)
- First description of the role of the ESCRT-III complex in regulated cell death (Cell 2017 – shared senior author)
- First detection of necroptosis in humans (Cell 2017 – shared senior author)
- First description of two separate pathways of regulated necrosis in one model in mice (PNAS 2013 – first author)
- First detection of non-cell autonomous necrosis in primary tissues (PNAS 2014 – first author)
- Detection of necroptosis as the central pathophysiological mechanism in ANCA vasculitis (PNAS 2017 – coauthor)
- First detection of ferroptosis in adrenocortical carcinomas (PNAS 2018 – senior author)
- First report of a combined inhibitor of necroptosis and ferroptosis (Nature Communications 2021 – senior author)
- Detection of steroids as sensitizers for ferroptosis (Science Advances 2022 – senior author)

Organization of Conferences

2013/14	Associate session organizer – TTS-World Transplant Congress (San Franc., USA)
2015	Organizer – Sandbjerg Symposium for Physiology (Sandbjerg, Denmark)
2016	Abstract Chair – ASN Kidney Week 2016 (Chicago, IL, USA)
2017	Organizer – Banbury Symposium on Regulated Necrosis (Cold Spring Harbor, USA)
2019	Organizer – European Cell Death Organization ECDO 2019- (Dresden, Germany)

Selected invited lectures:

This list excludes > 30 national and international seminar invitations, amongst which are invited seminars to the Ce-M-M, Vienna (**G. Superti-Furga**), Université Rene Decartes, Paris (**G. Kroemer**), Hospital Tenon, Paris (**P. Ronco**), UCL-Cancer Institute (**H. Walczak**), NIBS, Beijing (**X. Wang**), Columbia University, NYC (**B. Stockwell**), Mount Sinai Medical Center, NYC (**I. Daehn**), MSKCC, NYC (**S. Lowe**), Albert Einstein College of Medicine, NYC (**R. Kitis**), HMS, Boston (**J. Yuan**), HMS, Boston (**Joseph V. Bonventre**), Boston University (**S. Borkan**), Yale University, New Haven (**L. Cantley**), Emory University, Atlanta (**E. Mockarski**), Genentech, San Francisco (**V. Dixit**), Imperial College London (**D. Ma**), VIB Ghent (**P. Vandenabeele**), Semmelweis-

University, Budapest (**A. Szabo**), University of Magdeburg (**B. Schraven**), Soochou University, Suzhou (**S. He**), Shanghai University, Shanghai (**L. Sun**), University of Madrid, Madrid (**A. Ortiz**), University of Alabama, Birmingham (**A. Agarwal**), St. Jude Medical Center – Department of Immunology (**D. Green**), Columbia University, NYC (**J. Barasch** and **Q. Al-Awqati**), Starzl Center for Transplantation, Pittsburgh, PA (**V. Kagan** and **F. Lakis**).

1. “Fas Ligand mediates fratricide in renal proximal tubular cells *in vivo*.” **19. Jahrestagung der Deutschen Transplantationsgesellschaft 2010**, (selected abstract)
2. „RIP1-Mediated Necroptosis Essentially Contributes to Renal Ischemia/Reperfusion Injury.” **20. Jahrestagung der Deutschen Transplantationsgesellschaft 2011**, (selected abstract)
3. „Loss of Acid Sphingomyelinase Causes Defective Autophagy-induction *in vivo* and Sensitizes for Renal Ischemia/Reperfusion Injury.” **ASN 2012 – San Diego, CA**, Session on Acute kidney injury I. (selected abstract)
4. “Identification of two Independent Pathways that Regulate Necrosis *in vivo*.” **CSH Asia Non-apoptotic cell death 2013**, Shanghai, China. (selected abstract)
5. “Two different pathways of regulated necrosis mediate ischemia-reperfusion injury.” **ECDO-annual meeting 2013**, Paris. Session on “Emerging cell death pathways” (selected abstract)
6. “Programmed Necrosis in AKI.” **ASN 2013 – Atlanta, GA**, Session “Dying to know: New Cell Death Pathways in AKI” (invited speaker).
7. “Regulated Necrosis in Ischemia-Reperfusion Injury.” **AACR 2014 – San Diego, CA**, Major Symposium on “Novel pathways of non-apoptotic cell death” (invited speaker).
8. “The relative contribution of pathways of regulated necrosis to ischemic overall organ damage.” **Gordon Research Conference on Cell Death**, Mount Snow 06/14 (invited speaker).
9. “Necroptosis in Solid Organ Transplantation.” **World Transplant Congress – Sunrise Symposium (WTC2014)**, San Francisco 08/14 (invited speaker).
10. “Regulated Necrosis.” 19th Joint Meeting of the Signal Transduction Society, Weimar (invited honorary lecture associated with the STS science Award).
11. “The Necro-inflammatory auto-amplification loop of regulated necrosis and inflammation.” **Immunotherapy 2014**, La Havana, Cuba (invited speaker)
12. “50 ways or more to die.” **Joint British Transplantation Society and Nederlandse Transplantatie Vereniging Congress 2015 – Major Symposium**, Bournemouth, UK (invited speaker).
13. “Ferroptosis in Acute Kidney Injury.” **World Congress of Nephrology 2015** (ISN Annual Meeting 2015) (selected abstract)
14. “Beyond apoptosis and necroptosis: synchronized necrosis of renal tubules.” **International Symposium 2015 on Kidney Fibrogenesis**. Montabaur, Germany (invited speaker).
15. “Regulated Necrosis in Acute Kidney Injury.” **5th International Symposium on Molecular Targets in Renal Disease** (Bamberg, Germany). (invited speaker)
16. “Regulated Necrosis: Ferroptosis and permeability transition.” **Federation of European Physiological Societies (FEPS) meeting 2015 – major symposium**, Kaunas, Lithuania (invited speaker).
17. **Cold Spring Harbor Meeting “Cell Death” 2015** – (invited speaker – discussion leader).
18. “Trapped in the Iron Maiden – How kidneys die by ferroptosis!” **ECDO-annual meeting 2015**, Geneva (invited speaker)
19. **German Society of Nephrology (DGfN) annual meeting 2015** (Berlin, Germany). (invited speaker)
20. **German Society of Transplantation – annual meeting 2015** (Dresden, Germany). (invited speaker)
21. “Necroptosis and inflammation in AKI” **ASN 2015 – San Diego, CA**, Session on “Dead but not gone: cell death at the beginning of health and disease” (invited speaker)
22. **Cold Spring Harbor Asia Meeting “Targeting Cell Death Mechanisms for the Treatment of Human Diseases”**, Suzhou, China 2015 – (invited speaker).
23. **ERA-EDTA Annual Conference 2016**, “Novel concepts on Transplant Rejection”, Vienna, Austria, 2016 – (invited speaker).
24. **American Transplant Congress “Necroptosis in Transplantation”**, Boston, USA 2016 – (invited speaker)
25. “Phenytol inhibits necroptosis *in vitro* and *in vivo*.” **Gordon Research Conference on Cell Death**, Barcelona 06/16 (invited speaker).
26. “Regulated Cell Death Pathways and Allograft Rejection” **26th International Congress of The Transplantation Society**, Hong Kong, 08/2016 (invited speaker and discussion leader).
27. “Cellular Response to Signaling and Oxidative Stress: Suicide or Survival” **ASN 2016 – Chicago** (discussion leader)
28. “The Future of Clinical Trials for the Prevention of Regulated Necrosis.” **DEATH in the ALPS: Cell Death, Inflammation and Cancer** (invited speaker)
29. pMLKL detection in human kidney transplant biopsies – 2017 Fusion conference on Cell death and Inflammation (invited speaker)
30. Cold Spring Harbor - **Banbury-Symposium** – The *in vivo* relevance of ferroptosis (invited speaker and discussion leader)
31. Potential clinical trials for the prevention of Regulated Necrosis: Rockville NIH Symposium / Transplant panel (invited speaker)
32. Small molecules for the interference with Necroptosis and Ferroptosis - **ACS 2017, Philadelphia** (invited speaker)
33. Necroptosis in health and disease - **10th Tuscany Retreat on Cancer Research and Apoptosis – (Opening Plenary Lecture)**
34. NETs, Necroptosis and ANCA vasculitis **ECDO Conference on Cell Death**, Leuven, Belgium (selected abstract).
35. Regulated Necrosis as a therapeutic target - **SFB/TRR 127-autumn workshop – Venice, Italy** (keynote lecture)
36. Ferroptosis as a target in Transplantation – **German Transplant Society Meeting 2017** (invited speaker)
37. Necroptosis and Ferroptosis in Acute Kidney Injury – **ASN 2017 – New Orleans** (invited speaker)
38. Necroinflammation as a Driver and Novel Therapeutic Target of Autoimmunity. **2018 AKI/CRRT conference – San Diego, USA** (invited speaker)
39. Necroptosis and Ferroptosis as druggable targets – **FiMC 2018 Frontiers in Medicinal Chemistry – Jena, Germany** (keynote lecture)
40. Regulated Necrosis in Acute Kidney Injury – **German Society of Pathology meeting 2018 – Berlin** (keynote speaker)
41. Necroinflammation as a cause of kidney transplant rejection – **World Transplant Conference (TTS) 2018 – Madrid, Spain** (invited speaker)
42. Necroinflammation – **Montmartre Immunology Meeting 2018 – Paris, France** (invited speaker)
43. Necroinflammation as a driver of acute rejection – **American Transplant Congress 2018, Seattle** (invited speaker)
44. Regulated cell death pathways in transplantation - **American Transplant Congress 2018, Seattle** (invited speaker)
45. Ferroptosis as a novel target in Solid Organ Injury – **EMBO Workshop on Phagocytosis 2018 – Gent** (invited speaker)
46. New Kids on the Block: CD4+ T-Cell Populations in Autoimmune Kidney Diseases – **ASN 2018** (discussion leader)
47. Ferroptosis, Necroptosis and other pathways of regulated necrosis in AKI. – Session on “A Million Ways to Die in the Kidney” **ASN 2018** (invited speaker)
48. Necroinflammation as a Driver of Transplant Rejection – **27. Jahrestagung der Deutschen Transplantationsgesellschaft (Master Class) – Berlin** (invited speaker)
49. Immunological consequences of ferroptotic cell death – **Cold Spring Harbor Asia Meeting on Iron Dependent Cell Death 2018 – Suzhou, China** (invited speaker)
50. The Origin of Donor Specific Antibodies – **ISN Meeting 2019, Melbourne, Australia** (invited speaker and discussion leader)

51. Necrosis in Ischemia and Acute Organ Injury – 2nd Fusion Conference on Cell Death, Puerto Vallarta, Mexico (*invited speaker*)
52. Origin and Consequences of Necroinflammation – **16th Annual International Innate Immunity Conference**, Aegan Conferences, Rhodos, Greece (*invited speaker*)
53. Confused by the killers? Necroptosis, Pyroptosis and Ferroptosis in Acute Organ Injury – EKFS-Symposium Würzburg, Germany (*invited speaker*)
54. The role of Gasdermin D in diverse disease models (CSH meeting – Cell Death 2019) – Cold Spring Harbor, NY, USA (*invited speaker*)
55. Acute kidney injury - regulated cell death (necroptosis - ferroptosis), 31st European Congress of Pathology, Nice, France (*invited speaker*)
56. Ischemia and reperfusion injury in kidney transplantation (ESOT 2019), Copenhagen, Denmark (*invited speaker* and *discussion leader*)
57. 27th Euroconference on Apoptosis (ECDO 2019) – Dresden, Germany (*Chair of Organizing Committee*) – www.ecdo.eu/ecdo2019
58. Regulierte Nekrose in der Transplantationsmedizin – Jahrestagung der Deutschen Gesellschaft für Transplantationsmedizin (DTG 2019), Hannover, Germany (*invited speaker* and *session chair*)
59. Confused by the Killers? Necroptosis, Pyroptosis and Ferroptosis in Acute Kidney Injury and Transplantation, Jahrestagung 2019 Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Graz, Austria (*keynote speaker*)
60. Pathophysiology of Acute Kidney Injury – Austrian-Czech-Annual Meeting on Nephrology, Prague, Czech Republic (*invited speaker*)
61. Cell Death Propagation during Ferroptosis – FOR2036 symposium (SFB/TRR on BCL2) – Obergurgl, Austria (*invited speaker*)
62. Regulated Necrosis induced by nucleotide sensing – TRR 237 international meeting 2020 on “Defects of the innate immune system in autoinflammation and autoimmunity”, Dresden, Germany (*invited speaker*)
63. “Ferroptosis” – 2020 Canadian Transplant Summit – Manitoba, Canada (*invited speaker*)
64. The role of ferroptosis as a driver of kidney transplant rejection – 2020 Central European Meeting of Nephrology, Vienna, Austria (*invited speaker*)
65. The concept of necroinflammation. Jahrestagung der Deutschen Transplantationsgesellschaft 2020 – Cologne, Germany (*invited plenary lecture*)
66. “Ferroptosis in Endocrine Diseases” - Annual meeting – German Society of Endocrinology (*invited speaker*)
67. Keystone Meeting “DAMPs: “DAMPs in Transplantation” - Seoul, South Korea (*invited speaker* and *discussion leader*)
68. ESOT-Meeting Milan 2021 – The role of ferroptosis in transplantation (*invited speaker*)
69. Korean Society of Nephrology (KSN2021) – Seoul, Korea – New Strategies in AKI – Does Ferroptosis explain Nephron Loss? (*invited speaker*)
70. EMBO Conference on Ferroptosis – Munich, Germany – Ferroptotic cell death propagation in kidney tubules (*invited speaker*)

Funding to the Linkermann Lab:

1.	2008 - 2009 Else-Kröner-Fresenius-Stiftung <i>„Einfluss der Blockade des Zelltod-vermittelnden Komplexes aus Fas und Fas Ligand auf das akute Nierenversagen“</i>	50.000 €
2.	2009 - 2010 Intramurale Förderung der UK-SH <i>„Apoptoseblockade im akuten Kontrastmittel-induzierten Nierenversagen“</i>	30.000 €
3.	2010 - 2011 Hans-Werner Jackstädt Stiftung <i>„Pharmakodynamik und Pharmakokinetik von TAT-crmA im Mausmodell des akuten Nierenversagens“</i>	46.000 €
4.	2010 - 2011 Intramurale Förderung des UK-SH <i>„Apoptoseblockade im akuten Kontrastmittel-induzierten Nierenversagen“</i>	20.000 €
5.	2011 - 2012 DGfN Forschungsstipendium <i>„Analyse der Immunzell-unabhängigen Nekroptose nach Renaler Ischämie/Reperfusion“</i>	25.000 €
6.	2012 - 2013 Projektförderung der Firma Novartis <i>„Untersuchungen zu molekularen Mechanismen des programmierten Zelltods und Interventionsoptionen mittels TAT-RHIM“</i>	47.100 €
7.	2013 Projektförderung der Firma Novartis <i>„Untersuchungen zum programmierten Zelltod und Interventionsoptionen mittels TAT-RHIM in vivo“</i>	41.650 €
8.	2013 Pfizer International Grant <i>„Crosstalk between Rapamycin-induced Autophagy and Regulated Necrosis in Kidney Ischemia-Reperfusion Injury“</i>	39.900 €
9.	2013 - 2015 Projektförderung der Firma Fresenius <i>„Transplantation von Nekroptose-insensitiven Inselzellen zur Behandlung des Streptozozin-induzierten Diabetes Mellitus“</i>	120.000 €
10.	2013 - 2015 Hans-Werner Jackstädt Stiftung <i>„Mechanismen der Regulierten Nekrose im Akuten Nierenversagen“</i>	40.000 €
11.	2014 - 2017 German Research Foundation (EXC306) <i>„Control of inflammation by regulated necrosis from Hydra to man“</i>	802.928€
12.	2018 - 2021 Clinician Scientist (Wulf Tonnus) – SFB/TRR205 <i>“The Adrenal – Central Relay in Health and Disease”</i>	456.000€

13.	2019 - 2023 German Research Foundation (DFG) – Heisenberg Professorship <i>„Heisenberg-Professorship for Clinical Cell Death Research”, including a 5-year E14 funding for a senior postdoc (Anne von Mässenhausen, 378.000€)</i>	1.232.000€
14.	2019 - 2020 ECDO 2019 – DFG (30.500€) and TU Dresden (19.500€) <i>“International conference support“</i>	50.000€
15.	2020 - 2022 transCampus IRTG 2251 <i>“The role of zinc in ferroptosis”</i>	205.200€
16.	2020 - 2022 Else Kröner-Fresenius Stiftung - Translatorik <i>“The Role of Necroinflammation in Preclinical Porcine-to-non-Human Primate Kidney Xenotransplantation”</i>	698.076€
17.	2020 - 2023 Wilhelm-Sander-Stiftung <i>“Die Rolle der Regulierten Nekrose bei Adrenokortikalen Karzinomen und ihr therapeutisches Potential”</i>	183.930€
18.	2020 - 2024 German Research Foundation (DFG) – A5 of TRR127 <i>“Immunogenicity of islets of different clinically relevant sources in a preclinical humanized mouse model.” Funding 488.000€ (2021-2024) plus 61.000€ extension during COVID-19 crisis</i>	549.000€
19.	2021 - 2024 Priority Programme Ferroptosis (DFG-Schwerpunktprogramm) <i>“Steroid Hormones as Regulators of Ferroptosis Sensitivity During Acute Kidney Injury”</i>	190.164€
20.	2021 - 2025 German Research Foundation (DFG) – A01 of CRC/TRR205 <i>“Regulated Cell Death in Adrenal Inflammation and Septic Shock”</i>	531.529€
21.	2021 - 2026 DFG-IRTG 2251 (4.5 years) – Project 6 <i>1 x TV-L E13 (65%) for 4.5 years + 18.000 consumables per year + 24.570€ for experimental animals</i>	378.234€
22.	2022 - 2025 BMBF - Pathomechanisms (3 years) – Project 3 <i>“The role of oxidized phospholipids in non-cell-autonomous ferroptotic cell death and kidney IRI”</i>	599.888 €
Total funding:		<u>6.404.805 €</u>